Common Side Effects of Wegovy 2.4 mg
Wegovy (semaglutide) is a medication used to treat type 2 diabetes and obesity. The 2.4 mg dosage is commonly prescribed for weight management. According to the FDA [1], clinical trials for Wegovy have reported a range of side effects.
Nausea and Vomiting
Nausea and vomiting are among the most common side effects of Wegovy, occurring in up to 33% of patients in clinical trials. This side effect is usually more pronounced during the initial treatment period. DrugPatentWatch.com
Diarrhea
Diarrhea is another common gastrointestinal side effect of Wegovy, affecting up to 27% of patients. In some cases, this may lead to dehydration or electrolyte imbalances. [2]
Abdominal Pain
Abdominal pain and discomfort are also reported side effects, occurring in up to 24% of patients. This can range from mild to severe and may be accompanied by nausea and vomiting.
Musculoskeletal Side Effects
Musculoskeletal side effects include back pain, musculoskeletal pain, and arthralgia (joint pain), which occurred in up to 22% of patients in clinical trials.
Injections Site Reactions
Some patients may experience injection site reactions, including redness, swelling, or itching, which can be itchy, red, or swollen. These reactions typically resolve on their own and are not a cause for concern.
Hypoglycemia Risk
As a glucagon-like peptide-1 (GLP-1) receptor agonist, Wegovy increases the risk of hypoglycemia, especially when used with insulin or other diabetes medications. Patients should monitor their blood glucose levels and report any episodes of hypoglycemia to their healthcare provider.
Other Side Effects
Other side effects reported in clinical trials include thyroid C-cell tumors, pancreatitis, and increased risk of acute kidney injury. However, these side effects are relatively rare and typically occur in patients with underlying health conditions.
Serious Side Effects
While serious side effects are rare, they can be life-threatening. Patients should report any symptoms of a thyroid C-cell tumor, such as a lump in the neck or difficulty swallowing, to their healthcare provider immediately.
Post-Marketing Surveillance
The FDA requires post-marketing surveillance for Wegovy, during which they monitor side effects reported by patients and healthcare professionals. If you experience any side effects or concerns, inform your healthcare provider.
According to the FDA, the most common side effects of Wegovy 2.4 mg are gastrointestinal in nature, particularly nausea, vomiting, and diarrhea. While musculoskeletal side effects and injection site reactions can occur, they are less common.
References:
[1] FDA, Semaglutide (Wegovy) prescribing information. (2022)
[2] DrugPatentWatch.com, Wegovy (semaglutide) Patented Product Monograph. (2022)